Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE COMPOUND 65 versus ROXICET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE COMPOUND 65 versus ROXICET.
PROPOXYPHENE COMPOUND 65 vs ROXICET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is an opioid analgesic that binds to mu-opioid receptors in the central nervous system, resulting in inhibition of ascending pain pathways and alteration of pain perception. Acetaminophen component inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
Adults: 1 capsule (65 mg propoxyphene HCl + 650 mg acetaminophen) orally every 4 hours as needed; maximum 6 capsules per day.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
None Documented
None Documented
The terminal elimination half-life of propoxyphene is approximately 8-24 hours (mean 12 hours) in healthy adults. The half-life of its active metabolite, norpropoxyphene, is 30-36 hours, leading to prolonged effects and potential accumulation with repeated dosing, especially in renal impairment.
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Renal excretion of propoxyphene and its metabolites accounts for approximately 70-90% of an administered dose, with less than 5% excreted as unchanged drug. The remainder is eliminated via bile and feces. Minor amounts are excreted in breast milk.
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination